Breaking News: Six-State AI Pilot Denies Care Under Original Medicare
In a development raising alarms across the health care system, an AI-driven prior-authorization pilot attached to Original Medicare is leading to delays and denials in six states. The effort, launched at the start of 2026, uses a vendor-backed artificial intelligence review to decide whether certain procedures should be approved before services are performed. The move has prompted questions about patient access, provider burden, and the incentives embedded in the program.
What the WISeR Pilot Is Supposed to Do
The program is known as the Wasteful and Inappropriate Service Reduction Model, or WISeR, and it operates as a six-year pilot overseen by the Center for Medicare and Medicaid Innovation. It applies AI-powered prior authorization to a defined list of fee-for-service Medicare procedures. In practice, the AI makes a recommendation that a procedure be approved or denied, and those recommendations can become final decisions in many cases.
States in the Crosshairs and Services Affected
- Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington are the pilot states.
- Procedures under AI review include implantations of electrical nerve stimulators, sacral nerve stimulation for urinary issues, certain knee arthroscopy procedures, and related advanced therapies.
Six months into the program, doctors and patient groups report a notable drop in approval rates for these services when compared with traditional Medicare approvals and with what beneficiaries experience under Medicare Advantage plans.
Why This Matters for Original Medicare Enrollees
Critics say the medicare program already denying access to needed care for some seniors, particularly when AI-driven decisions collide with complex medical needs. The friction is most acute for patients who rely on highly specialized devices or surgical interventions where timing can affect outcomes. Advocates warn that delays can translate into worse pain, reduced mobility, or longer hospital stays.
Supporters of WISeR contend the pilot targets waste and fosters accountability. They argue that AI can flag low-value or duplicative care, potentially saving taxpayers money and reallocating resources to urgent needs. The tension sits at the intersection of coverage, patient rights, and the ethics of automated decision-making.
Voices from the Front Lines
"In my practice, the AI review adds another hurdle for patients who already face daunting medical decisions," said Dr. Lila Mendes, a spine surgeon in Phoenix. "We’re seeing cases where approvals come after weeks of back-and-forth, and the period of jeopardy is real for people with chronic pain."
nurse practitioner Hannah Klein from an Ohio clinic adds, "The process feels opaque. Patients and families ask why decisions are being made, and there isn’t a straightforward appeals path that’s easy to navigate in a time-sensitive setting."
Sen. Maria Cantwell, a longtime critic of opaque administrative processes, has pressed the administration for more transparency and tighter controls around the AI decision rules. She has called for audits of denial patterns and clearer deadlines for when and how patients can appeal AI-generated determinations.
How AI Decisions Are Made—and Why Critics Are Worried
The WISeR model relies on external AI review vendors that analyze clinical data, procedure codes, and prior authorization history to produce a recommendation. Several key concerns have emerged:
- Incentives: Vendors receive compensation tied to the projected savings they deliver to Medicare, creating a potential conflict where fewer approvals equal higher perceived savings.
- Transparency: Clinicians and patients often don’t see the exact criteria the AI uses to deem a service necessary or unnecessary.
- Consistency: Denial rates reportedly vary by state and by type of service, complicating out-of-pocket planning for families.
Numbers, Timeframes, and Real-World Impact
- Start date: January 1, 2026, with a six-year horizon for the WISeR pilot.
- Pilot states: Arizona, New Jersey, Ohio, Oklahoma, Texas, Washington.
- Service categories: nerve stimulators, urinary incontinence procedures, certain knee surgeries, and related devices.
- Timelines: patients and providers report longer wait times for decisions than federal deadlines call for, in several cases stretching past the target review window.
Policy analysts caution that these delays are not merely administrative nuisances. For patients living with chronic conditions, every day of postponed care can mean increased pain, reduced function, and higher risk of complications. In some instances, urgent devices or implants have been deferred while the AI decision is finalized.
Investor and Market Considerations
Investors and health-tech firms are watching the WISeR pilot closely. The model has potential implications for the growth of AI-enabled healthcare services and for contractors that provide automated decision support to Medicare. Analysts warn that policy changes, clarifications, or reversals could lead to volatility in the health-tech segment that targets government programs.
By design, the pilot could steer future contracts toward AI vendors with the strongest demonstrated safeguards and patient-outcome data, rather than just the lowest upfront costs. That dynamic is shaping discussions about how the government buys AI tools for clinical decision support and the long-term risks and rewards for investors in this space.
What Comes Next—and What It Means for Beneficiaries
Lawmakers on both sides of the aisle have signaled they want more oversight, better access to information about AI decision logic, and clearer pathways for appeals. Some call for an independent evaluation of the pilot’s impact on patient outcomes, not just cost savings.
For beneficiaries, the pressing questions are straightforward: How do I appeal a denial based on AI review? What documentation should I bring if a decision hinges on automated criteria? And how will delays be mitigated if my condition is time-sensitive?
Bottom Line: A Policy Experiment with Real-Life Stakes
The medicare program already denying access through AI-driven pre-authorization—especially when it affects seniors with limited mobility or severe pain—poses a clear challenge to the promise of Original Medicare. As the six-state pilot progresses, patients, clinicians, and policymakers will watch closely to determine whether automated reviews can protect taxpayers while safeguarding timely, high-quality care for older Americans.
Key Takeaways for the Investing Community
- The WISeR pilot represents a notable test case for AI in government-funded health care, with potential implications for service delivery, vendor profitability, and stock-market perceptions of health-tech firms.
- Any shift in policy or tightening of safeguards could affect contracts, vendor dynamics, and future opportunities in Medicare-related AI solutions.
- Clear, patient-centered guidelines and robust transparency will be essential to sustain confidence among beneficiaries and investors alike.
Discussion